Background: Type 2 airway inflammation plays a central role in the pathogenesis of allergen-induced asthma, but the underlying mechanisms remain poorly understood. Recently, we demonstrated that reduced mucociliary clearance, a characteristic feature of asthma, produces spontaneous type 2 airway inflammation in juvenile b-epithelial Na 1 channel (Scnn1b)-transgenic (Tg) mice. Objective: We sought to determine the role of impaired mucus clearance in the pathogenesis of allergen-induced type 2 airway inflammation and identify cellular sources of the signature cytokine IL-13. Methods: We challenged juvenile Scnn1b-Tg and wild-type mice with Aspergillus fumigatus and house dust mite allergen and compared the effects on airway eosinophilia, type 2 cytokine levels, goblet cell metaplasia, and airway hyperresponsiveness. Furthermore, we determined cellular sources of IL-13 and effects of genetic deletion of the key type 2 signal-transducing molecule signal transducer and activator of transcription 6 (STAT6) and evaluated the effects of therapeutic improvement of mucus clearance. Results: Reduced mucociliary allergen clearance exacerbated Stat6-dependent secretion of type 2 cytokines, airway eosinophilia, and airway hyperresponsiveness in juvenile Scnn1b-Tg mice. IL-13 levels were increased in airway epithelial cells, macrophages, type 2 innate lymphoid cells, and T H 2 cells along with increased Il33 expression in the airway epithelium of Scnn1b-Tg mice. Treatment with the epithelial Na 1 channel blocker amiloride, improving airway surface hydration and mucus clearance, reduced allergen-induced inflammation in Scnn1b-Tg mice. Conclusion: Our data support that impaired clearance of inhaled allergens triggering IL-13 production by multiple cell types in the airways plays an important role in the pathogenesis of type 2 airway inflammation and suggests therapeutic improvement of mucociliary clearance as a novel treatment strategy for children with allergen-induced asthma. Type 2 airway inflammation characterized by the signature type 2 cytokine IL-13 plays a central role in the pathogenesis of asthma and has been associated with disease severity in patients with other chronic inflammatory lung diseases (COPD), such as chronic obstructive pulmonary disease and cystic fibrosis (CF). [1] [2] [3] [4] [5] [6] Emerging evidence suggests that the airway epithelium is a central player in the orchestration of type 2 inflammation in response to inhaled allergens and other environmental stimuli, [7] [8] [9] [10] but the mechanistic links between epithelial (dys)function and allergic airway inflammation remain poorly understood. Previous studies demonstrated that asthma is associated with impaired mucociliary clearance (MCC) in patients, [11] [12] [13] and longitudinal studies in bepithelial Na 1 channel (Scnn1b) transgenic (Tg) mice showed that reduced MCC produces spontaneous type 2 airway inflammation with increased IL-13 levels, airway eosinophilia, mucus hypersecretion, and signatures of alternative macrophage activation at juvenile ages that precedes the chronic neutrophilic airway disease observed in adult Scnn1b-Tg mice. [14] [15] [16] [17] In Scnn1b-Tg mice impaired MCC is caused by airway surface dehydration (mucus hyperconcentration), an epithelial dysfunction that can either result from defects in epithelial ion/fluid transport, as in patients with CF, 18, 19 or from mucin hypersecretion under conditions of chronic airway inflammation and might therefore provide a mechanism underlying mucociliary dysfunction in a spectrum of obstructive lung diseases, including asthma and chronic bronchitis. [20] [21] [22] [23] [24] Because efficient MCC is an important innate defense mechanism that clears inhaled allergens and other noxious stimuli constantly from the lungs 11 and because direct activation of the epithelium by airborne allergens through pattern recognition receptors was shown to be sufficient to induce type 2 airway inflammation, 9, 25 we hypothesized that reduced mucus clearance might slow the clearance of aeroallergens, which could trigger innate and/or adaptive immune responses that orchestrate type 2 airway inflammation in juvenile mice with a type 2-biased immune system. 14, 26, 27 Second, based on previous studies demonstrating that pharmacologic improvement of airway surface hydration by the epithelial Na 1 channel (ENaC) blocker amiloride or by the osmotically active agent hypertonic saline can enhance reduced MCC in patients with chronic airway diseases including asthma, [28] [29] [30] we hypothesized that this approach might reduce allergen-induced type 2 inflammation in mucostatic airways in vivo.
To test this hypothesis, we challenged juvenile Scnn1b-Tg mice and wild-type (WT) littermates using intratracheal application of Aspergillus fumigatus and house dust mite (HDM) extracts as naturally occurring aeroallergens and compared allergen clearance and effects on type 2 airway inflammation, goblet cell metaplasia (GCM), mucin expression, and airway hyperresponsiveness (AHR). To identify cellular sources of the signature type 2 cytokine IL-13, we performed immunohistochemistry, transcript analysis in microdissected native airway epithelia and highly differentiated primary tracheal epithelial cultures, and flow cytometry of innate and adaptive immune cells from lungs of naive and A fumigatus-challenged juvenile Scnn1b-Tg and WT mice. Furthermore, we determined the role of IL-13/signal transducer and activator of transcription 6 (STAT6) signaling in allergen-induced airway inflammation by means of genetic deletion of the key signal-transducing molecule STAT6 in Scnn1b-Tg mice. [31] [32] [33] Finally, we evaluated the effects of pharmacologic improvement of airway surface hydration and mucus transport by amiloride on allergen-induced airway inflammation and AHR in Scnn1b-Tg and WT mice.
METHODS
Further details on the methods used in this study can be found in the Methods section in this article's Online Repository at www.jacionline.org.
Experimental animals
All animal studies were approved by the Regierungspr€ asidium Karlsruhe, Germany. Scnn1b-Tg mice were generated, as previously described.
18 Stat6
2/2
mice (Jackson Laboratories, Bar Harbor, Me) 31 were intercrossed with Scnn1b-Tg mice to obtain Scnn1b-Tg/Stat6 2/2 , Scnn1b-Tg, Stat6
, and WT littermates. Mice were studied at neonatal (10 days old), juvenile (2-3 weeks old), and adult (6 weeks old) ages.
Allergen exposure
Juvenile mice were challenged with 20 mL and adult mice were challenged with 50 mL of A fumigatus (2 mg/mL in NaCl 0.9%; Hollister-Stier, Spokane, Wash) every 48 hours by means of intratracheal instillation a total of 4 times, as previously described. 34 Exposure to HDM (Greer laboratories, Lenoir, NC) was started by using intratracheal instillation of 10 mg (20 mL of 0.5 mg/ml in NaCl 0.9%) on 2 consecutive days, followed by 2 intratracheal instillations of 1 mg (20 mL of 0.05 mg/mL in NaCl 0.9%) on days 11 and 12 after the first challenge. 27 Control groups were instilled with vehicle (NaCl 0.9%) alone.
Amiloride treatment
Mice were treated with intranasal instillation of amiloride (10 mmol/L, 1 mL/g body weight, 3 times per day) or vehicle (double-distilled H 2 O [ddH 2 O]) alone for a period of 3 weeks, as previously described. 35 In the presence of amiloride treatment, mice were exposed to A fumigatus or HDM, as detailed in the Methods section in this article's Online Repository.
AHR
AHR was measured in anesthetized and paralyzed mice by means of exposure to aerosol containing increasing concentrations of methacholine (range, 0.33-160 mg/mL) with a small-animal ventilator (flexiVent; SCIREQ, Montreal, Quebec, Canada), as previously described. 36 MCC, allergen clearance, and allergen uptake studies MCC was determined based on elimination of yellow-green fluorescent microspheres from trachea (Thermo Fisher Scientific, Waltham, Mass), and whole-lung and airway allergen clearance were determined from the elimination of fluorescently labeled A fumigatus (Alexa Fluor 647 Microscale Protein Labeling Kit; Life Technologies, Darmstadt, Germany) from lung homogenates and bronchoalveolar lavage (BAL) fluid, respectively, after intratracheal instillation. 37, 38 Allergen uptake by bronchoalveolar macrophages (AM) and conventional dendritic cells (cDCs) in vivo and in vitro was determined from the frequency of cells containing fluorescently labeled A fumigatus 4 hours after intratracheal instillation of mice or incubation of BAL cells, respectively, by using a LSRFortessa analyzer and FACSDiva software (v8.0.1; BD Biosciences, Heidelberg, Germany), as previously described. 39, 40 BAL cell counts and type 2 cytokine measurements BAL and differential cell counts were performed, as previously described.
14 IL-4, IL-5, and IL-13 levels were measured in BAL supernatants by using ELISA (R&D Systems, Minneapolis, Minn) or a Cytometric Bead Array Enhanced Sensitivity Flex Set (BD Biosciences), according to the manufacturer's instructions.
Flow cytometry
Single-cell suspensions were obtained from perfused lungs and restimulated in vitro with 50 ng/mL phorbol 12-myristse 13-acetate and 1 mg/mL ionomycin (Sigma-Aldrich, Taufkirchen, Germany). Cells were surface stained with specific fluorescently labeled antibodies to delineate cellular populations, as previously described 41, 42 and detailed in the Methods section in this article's Online Repository. For detection of IL-13, cells were fixed, permeabilized (BD Biosciences), and incubated with intracellular antibodies against IL-13 (eBioscience, San Diego, Calif). Multiparameter flow cytometry was performed with an LSRFortessa, and data were analyzed with FACSDiva (version 8.0.1; BD Biosciences) or FlowJo (version 10; TreeStar, Ashland, Ore) software.
Histology and airway morphology
Histology and analyses of GCM were performed, as previously described. 14 
Laser microdissection
Laser microdissection of the airway epithelium was performed in 10-mm sections of frozen lungs by using a 337-nm nitrogen laser (MicroBeam system; PALM Microlaser Technologies, Bernried, Germany), and total RNA was isolated with the RNeasy Micro Kit (Qiagen, Hilden, Germany).
Immunohistochemistry
Immunohistochemical staining for IL-13 was performed with a polyclonal goat anti-mouse IL-13 antibody (R&D Systems), as previously described. 43, 44 Primary tracheal epithelial cultures Primary tracheal epithelial cells were isolated and cultured on membranes (Costar, Cambridge, Mass) under air-liquid interface (ALI) conditions, as previously described. 45 After reaching confluence (approximately 14 days), IL-33 (10 ng/mL; R&D Systems, Wiesbaden, Germany) or ionomycin (1 mg/mL, Sigma-Aldrich) was added for 24 or 4 hours, respectively, and total RNA was extracted (RNeasy Plus Mini Kit; Qiagen). For inhibition of the IL-33/ST2 signaling pathway, cultures were pretreated with anti-ST2 antibody (30 mg/mL; R&D Systems), the myeloid differentiation primary response gene-88 (MyD88) inhibitory peptide Pepinh-MYD (50 mM; InvivoGen, San Diego, Calif), or the p38 mitogen-activated protein (MAP) kinase inhibitor SB203580 (20 mmol/L; InvivoGen).
Real-time RT-PCR
Real-time RT-PCR was performed by using TaqMan gene expression assays for Il13, Il33, Il25, thymic stromal lymphopoietin (Tslp), periostin (Postn), Mmp12, Chia, Ym1, Ym2, Arg1, Muc5ac, Muc5b, Gob5, and the b-actin gene (Actb; Applied Biosystems, Darmstadt, Germany) and analyzed, as previously described. (Fig 1, A) and whole-lung (Fig 1, B) and airway (Fig 1, C) allergen clearance in juvenile (2-to 3-week-old) WT and Scnn1b-Tg mice (n 5 4-13 for each group). *P < .05, **P < .01, and ***P < .001 compared with WT mice. D-H, Juvenile WT and Scnn1b-Tg mice were challenged with A fumigatus (Af) or vehicle alone. Fig 1, D . Fig 1, E-G, IL-4 , IL-5, and IL-13 in BAL fluid (n 5 9-11 for each group). Fig 1, H, Goblet cells (n 5 17-25 for each group). *P < .05 and ***P < _ .001 compared with vehicle-treated mice of the same genotype. P < .05, àP < .01, and §P < .001 compared with mice with the same treatment but different genotype. I and J, Assessment of AHR in naive juvenile WT and Scnn1b-Tg mice (Fig 1, I ) and after A fumigatus exposure (Fig 1, J ; n 5 7-14 for each group). (Fig 2, B) and AHR (Fig 2,  C) were determined (n 5 7-17 mice for each group). P < .05 and àP < .01 compared with mice with the same treatment but different genotype. D-K, Expression of the type 2 signature genes Il13 (Fig 2, D) , Muc5ac (Fig 2, E) , Gob5 (Fig 2, F) , Arg1 (Fig 2, G) , Mmp12 (Fig 2, H) , Ym1 (Fig 2, I ), Ym2 (Fig 2, J) , and Chia (Fig 2, K) in naive neonatal (10-day-old), juvenile (3-week-old), and adult (6-week-old) WT and Scnn1b-Tg mice (n 5 7-16 mice for each group). *P < .05, **P < .01, and ***P < .001 compared with mice with the same age but different genotype. P < .05, àP < .01, and §P < .001 compared with neonatal mice with the same genotype. #P < .05 and {P < .01 compared with juvenile mice with the same genotype.
Statistics
Data were derived from at least 3 independent experiments and analyzed with SigmaPlot version 12.5 software (Systat Software, Erkrath, Germany) and SPSS Statistics software (version 22; IBM, Ehningen, Germany) and are reported as means 6 SEMs. Statistical analyses were performed with the Student t test, Mann-Whitney rank sum test, or 1-way ANOVA, as appropriate, and a P value of less than .05 was accepted to indicate statistical significance.
RESULTS
Impaired allergen clearance exacerbates allergeninduced type 2 airway inflammation and AHR in juvenile Scnn1b-Tg mice To determine the effects of mucociliary dysfunction on allergen clearance and allergen-induced airway disease, we challenged 2-to 3-week-old juvenile Scnn1b-Tg and WT mice with intratracheal application of the natural aeroallergen A fumigatus or vehicle alone and compared allergen clearance, inflammatory cell counts, and levels of the type 2 cytokines IL-4, IL-5, and IL-13 in BAL fluid; parameters of mucus hypersecretion (ie, GCM and mucin expression); and AHR (Fig 1 and see Fig E1 in this article's Online Repository at www.jacionline.org). MCC and clearance of A fumigatus from whole lungs and from airway lumen were significantly reduced in naive Scnn1b-Tg mice compared with values in WT littermates (Fig 1, A-C) . To test whether reduced allergen clearance exacerbates allergeninduced airway disease, we first used a short-term challenge protocol consisting of 4 A fumigatus challenges. In WT mice this challenge induced a modest increase in BAL macrophage counts, eosinophil counts, and IL-5 and IL-13 levels (Fig 1, D-G) . In Scnn1b-Tg mice BAL fluid eosinophil counts and IL-4, IL-5, and IL-13 levels were spontaneously increased, 14, 15 and A fumigatus challenge triggered robust airway eosinophilia and production of IL-4, IL-5, and IL-13 that was significantly increased compared with allergen-induced responses in WT mice (Fig 1, 
D-G). Type 2 airway inflammation in A fumigatus-challenged
WT mice was associated with GCM and increased transcript levels of Muc5ac, Muc5b, and Gob5 (Fig 1, H , and see Fig E1) . Vehicle-treated Scnn1b-Tg mice showed spontaneous GCM and increased expression of Muc5ac, Muc5b, and Gob5 that was not further increased by A fumigatus challenge (see Fig E1) . Invasive pulmonary function testing demonstrated spontaneous AHR in naive juvenile Scnn1b-Tg versus WT mice (Fig 1, I ). In the challenge model A fumigatus aggravated AHR in juvenile Scnn1b-Tg mice but did not produce AHR in WT littermates (Fig 1, J) .
In contrast to juvenile mice, short-term A fumigatus challenge did not produce airway eosinophilia and increased IL-13 levels in 6-week-old adult WT mice (Fig 2, A and B) . In adult Scnn1b-Tg mice, consistent with previous studies, eosinophilia and increased IL-13 levels in BAL fluid were diminished and airway inflammation was dominated by neutrophils, 14 and A fumigatus challenge induced neither type 2 inflammation nor AHR (Fig 2, A-C) .
To determine the relationship between this age-dependent susceptibility to allergen challenge and previously reported skewing toward type 2 immunity in neonatal mice, 14 ,26,27 we compared expression levels of a set of type 2 signature genes, including Il13, Muc5ac, Gob5, Arg1, Mmp12, Ym1, Ym2, and Chia, 46 in lung tissues from WT and Scnn1b-Tg mice at neonatal (10 days old), juvenile, and adult ages (Fig 2, D-K ). Consistent with a type 2-biased immune system in the neonatal period, several type 2 signature genes (Il13, Muc5ac, Gob5, Arg1, and Ym2) were significantly increased in neonatal compared with older WT mice (Fig 2, D-K) . At all age groups, expression levels of all of these type 2 signature genes were increased in Scnn1b-Tg versus WT mice; however, these differences waned for most signatures at the age of 6 weeks (Fig 2, D-K) . These data confirm skewing toward type 2 immunity in neonatal mice and show that this disposition is associated with increased susceptibility to allergen-induced type 2 airway inflammation in juvenile WT In HDM-exposed Scnn1b-Tg mice severe airway obstruction and mucus plugging of cannulae impeded ventilation, and measurements had to be discontinued at methacholine concentrations of greater than 32 mg/mL. N 5 13 to 23 for each group. *P < .05, **P < .01, and ***P < .001 compared with vehicle-treated mice of the same genotype. P < .05, àP < .01, and §P < .001 compared with mice with the same treatment but different genotype.
J ALLERGY CLIN IMMUNOL VOLUME 140, NUMBER 1 each group). *P < .05 and **P < .01 compared with vehicle-treated cultures of the same genotype (Fig 4, D) or compared with IL-33-treated WT cultures (Fig 4, E) mice, as well as exaggerated responses in Scnn1b-Tg mice with impaired allergen clearance. Next, we tested the effects of HDM in juvenile WT and Scnn1b-Tg mice using a protocol consisting of intratracheal sensitization, followed by challenge to determine the role of impaired MCC in an independent allergen model (Fig 3) . In WT mice HDM induced increased levels of eosinophils, CD4
1 T cells, IL-4, IL-5, IL-13, and AHR (Fig 3) . In Scnn1b-Tg mice BAL fluid eosinophil counts, type 2 cytokine levels, and AHR were increased at baseline, and similar to A fumigatus, these phenotypes were significantly exacerbated by HDM (Fig 3) . Taken together, these results demonstrate that mucociliary dysfunction impairs allergen clearance and aggravates type 2 inflammation and AHR in juvenile Scnn1b-Tg mice.
Airway epithelial, innate, and adaptive immune cells contribute to exaggerated allergen-induced type 2 inflammation in Scnn1b-Tg mice
To determine the cellular sources of IL-13 in type 2 airway inflammation, we performed immunohistochemistry in lung sections from juvenile Scnn1b-Tg and WT mice challenged with A fumigatus or vehicle alone. Distinct IL-13 immunoreactive signals were detected in epithelial cells lining the conducting airways of vehicle-treated Scnn1b-Tg mice but not WT littermates (Fig 4, A and B) . Challenge with A fumigatus increased the number of IL-13 1 airway cells in WT and Scnn1b-Tg mice slightly; however, this trend did not reach statistical significance (Fig 4,  A and B) . For independent confirmation of these results, we isolated airway epithelial cells from frozen lung sections using laser microdissection and determined transcript levels of the key type 2 cytokine Il13. Furthermore, we measured expression levels of Il33, Il25, and Tslp, epithelial cytokines that were shown to be secreted in response to allergen exposure and promote type 2 airway inflammation through activation of T H 2 cells, type 2 innate lymphoid cells (ILC2s), and cDCs, 7, 9, 25, 47 and Postn, which was also shown to be expressed by epithelial cells and implicated in type airway 2 inflammation. 48 Il13, Il25, and Tslp transcripts were not detectable in microdissected airway epithelia from WT mice, whereas Il33 and Postn were readily detected, even without A fumigatus challenge (Fig 4, C) . In naive Scnn1b-Tg mice epithelial Il13 and Il33 expression was significantly increased, Il25 and Tslp were not detected, and Postn mRNA levels were not changed compared with those in WT mice (Fig 4, C) . In airways from A fumigatus-challenged Scnn1b-Tg mice, Il13 mRNA levels tended to be approximately 3-fold higher; however, this difference did not reach statistical significance. Transcript levels of Il25 and Tslp remained undetectable, and Il33 and Postn did not differ in A fumigatus-challenged versus naive Scnn1b-Tg mice (Fig 4, C) .
To test whether airway epithelial cells are capable of expressing Il13 in vitro, we measured Il13 transcripts in highly differentiated primary tracheal epithelial cell cultures at baseline and after stimulation with recombinant IL-33 or ionomycin (Fig 4, D) . Il13 was not detected under basal conditions but was induced in a dose-dependent fashion by IL-33 and by nonspecific stimulation with ionomycin in tracheal epithelial cultures from WT and Scnn1b-Tg mice (Fig 4, D , and see Fig E2 in this article's Online Repository at www.jacionline.org). IL-33-induced Il13 expression did not depend on signal transducer and activator of transcription 6 (STAT6) signaling in vitro but was blocked by inhibitors of the IL-33/ST2 signaling pathway, including anti-ST2 antibody, the MyD88 inhibitory peptide Pepinh-MYD, and the p38 MAP kinase inhibitor SB203580 (Fig 4, D and E) .
To determine whether innate or adaptive immune cells contributed to increased baseline and A fumigatus-induced expression of IL-13 in Scnn1b-Tg mice (Fig 1, G) , we isolated leukocytes from lungs and measured IL-13 expression in different subpopulations by using flow cytometry (Fig 4, F) . In lungs from WT mice, numbers of IL-13 1 cells in the different leukocyte subpopulations were low and did not change in response to short-term A fumigatus challenge. In naive Scnn1b-Tg mice IL-13
1 T H 2 cell, AM, B-cell, and ILC2 counts were significantly increased compared with those in WT mice (Fig 4, F) , and IL-13
1 T H 2 cells and IL-13 1 ILC2 counts were further increased after A fumigatus challenge (Fig 4, F) .
Collectively, these data show that airway epithelial cells and innate and adaptive immune cells provide sources of IL-13 in spontaneous and exaggerated allergen-induced type 2 airway inflammation in juvenile Scnn1b-Tg mice and indicate that the release of epithelial IL-33 contributes to this process in vivo.
Alternative macrophage activation and allergen challenge in Scnn1b-Tg mice Because previous studies showed signatures of alternative macrophage activation in Scnn1b-Tg mice 16, 49 and alternatively activated macrophages (AAMs) have been implicated in type 2 inflammation, 50, 51 we next determined activation markers of AMs and the capacity of A fumigatus uptake by AMs and cDCs in vivo and in vitro by using flow cytometry (Fig 5) . Compared with WT mice, Scnn1b-Tg mice showed significant upregulation of CD11b on AMs, as defined by F4/80 1 CD11c hi CD3
2
, indicating macrophage activation (Fig 5, A and B) . Upregulation of the scavenger receptors CD206 and CD301 confirmed the presence of AAMs (Fig 5, C and D) . CD206 and CD301 were already increased in vehicle-treated Scnn1b-Tg mice and reduced by approximately 15% to 25% after A fumigatus challenge (Fig 5,  C and D) . The uptake of fluorescently labeled A fumigatus by AMs from naive Scnn1b-Tg mice was significantly reduced compared with that in WT mice in vivo and in vitro (Fig 5, E  and F) . Conversely, uptake of A fumigatus by lung cDCs was significantly increased in Scnn1b-Tg mice (Fig 5, G and H) . These data demonstrate robust AM activation in mucostatic airways of naive Scnn1b-Tg mice but indicate that AAMs do not play a major role in exaggerated allergen-induced type 2 inflammation.
Lack of STAT6 abrogates type 2 airway inflammation in Scnn1b-Tg mice
The key type 2 signaling molecule IL-13 exerts its effector functions through STAT6 signaling. [31] [32] [33] To determine whether increased IL-13 plays a causal role in baseline and/or exaggerated allergen-induced type 2 inflammation, we challenged juvenile Stat6-deficient Scnn1b-Tg (Scnn1b-Tg/Stat6 2/2 ) mice and Scnn1b-Tg littermates with A fumigatus or vehicle alone and compared their pulmonary phenotypes. Spontaneous eosinophilic airway inflammation, IL-13, and GCM observed in naive Scnn1b-Tg mice were significantly reduced in Scnn1b-Tg/Stat6 2/2 mice (Fig 6, A-C) . Furthermore, Scnn1b-Tg/Stat6 2/2 mice were protected from A fumigatus-induced airway eosinophilia, increased expression of IL-13, and GCM (Fig 6, A-C) . IL-13 immunoreactive signals detected in lung sections from Scnn1b-Tg mice were abrogated in Scnn1b-Tg/Stat6 2/2 mice (Fig 6, D) . Taken together, these data show that IL-13/STAT6 signaling plays a critical role in the exaggerated type 2 inflammatory response observed on allergen challenge in juvenile Scnn1b-Tg mice.
Preventive amiloride treatment reduces allergeninduced type 2 inflammation and AHR in Scnn1b-Tg mice Previous studies demonstrated that improvement of airway surface hydration by means of preventive treatment with the ENaC blocker amiloride reduced airway mucus obstruction and spontaneous type 2 airway inflammation in juvenile Scnn1b-Tg mice. 35 To test whether allergen-induced inflammation can be prevented by ENaC inhibition, we treated newborn Scnn1b-Tg mice and WT control animals with airway instillation of amiloride or vehicle alone for 3 weeks and superimposed an allergen challenge with A fumigatus or HDM in the presence of this treatment regimen (Fig 7, A and E) . Preventive amiloride treatment significantly reduced exacerbated A fumigatus-and HDMinduced eosinophilia and IL-13 levels in BAL fluid from Scnn1b-Tg mice (Fig 7, A-H) . Furthermore, amiloride treatment prevented HDM-induced AHR in Scnn1b-Tg mice (Fig 7, J) . These data demonstrate that improvement of airway surface hydration by means of pharmacologic inhibition of ENaC protected juvenile Scnn1b-Tg mice from allergen-induced type 2 airway inflammation.
DISCUSSION
Type 2 airway inflammation is a key feature of allergeninduced asthma and has recently been implicated in patients with other common chronic inflammatory lung diseases, including COPD and CF. [1] [2] [3] [4] [5] [6] However, the underlying risk factors and mechanisms that trigger and sustain allergic airway inflammation remain poorly understood. By using juvenile Scnn1b-Tg mice in combination with 2 independent models of allergen-induced asthma (A fumigatus and HDM), for the first time, this study demonstrates that impaired MCC with reduced clearance of inhaled aeroallergen constitutes a risk factor of type 2 inflammation that aggravates allergen-induced secretion of IL-13 and characteristic phenotypes of allergic airway disease, including airway eosinophilia and AHR in vivo (Figs 1 and 3) . Furthermore, our data yield novel insights into the role of the airway epithelium and cells of the innate and adaptive immune system in the pathogenesis of type 2 inflammation in mucostatic airways (Figs 4 and 5) . Analysis of Scnn1b-Tg mice with genetic deletion of Stat6 confirmed a role of the canonical IL-4/IL-13-STAT6 immune axis in the type 2 nature of the exaggerated immune response toward allergen challenge (Fig 6) . Finally, we provide proof of concept that pharmacologic improvement of mucus clearance is an effective therapeutic strategy to prevent exaggerated allergen-induced type 2 inflammation and AHR in mucostatic airways from Scnn1b-Tg mice (Fig 7) .
Previous studies demonstrated that IL-13 is a central signaling molecule that is sufficient to produce the key features of type 2 airway inflammation, including airway eosinophilia, GCM, mucus hypersecretion, and AHR in vivo, 1-3 and identified T H 2 cells, ILC2s, and AAMs as cellular sources of IL-13 production. 8, 50 Interestingly, our immunohistochemistry studies in lung sections and transcript analysis of microdissected airways detected robust expression of IL-13 in airway epithelial cells from Scnn1b-Tg mice at baseline and after A fumigatus challenge (Fig 4) . In contrast to airway tissues, spontaneous Il13 expression was not detectable in primary airway epithelial cultures from (Fig 7, A) , and BAL fluid total cell counts (Fig 7, B) , eosinophil counts (Fig 7, C) , and IL-13 levels (Fig 7, D) were determined (n 5 14-49 in WT groups and n 5 4-9 in Scnn1b-Tg groups). E-J, Alternatively, sensitization and challenge with HDM or vehicle (NaCl 0.9%) alone was superimposed to amiloride (Fig 7, E) , and BAL total inflammatory cell counts (Fig 7, F) , eosinophil counts (Fig 7, G) , IL-13 levels (Fig 7, H) , and AHR (Fig 7, I , WT mice; Fig 7, J, Scnn1b-Tg mice) were determined (n 5 13-23 in WT groups and n 5 16-28 in Scnn1b-Tg groups). *P < .05, **P < .01, and ***P < .001 compared with vehicle-treated (ddH 2 O and NaCl 0.9%) mice of the same genotype. P < .05, àP < .01, and §P < .001 compared with vehicle-treated (H 2 O) A fumigatus (Af) or HDMinduced mice of same genotype.
Scnn1b-Tg mice in vitro, suggesting that Il13 expression required epithelial cell activation in vivo (Fig 4, D) . Recent studies demonstrated that the airway epithelium acts as a sentinel that can sense allergens and other noxious stimuli, such as viruses, on airway surfaces through a range of pattern recognition receptors and that activation by these stimuli leads to the release of epithelial cytokines, such as IL-33, IL-25, and TSLP, which in turn participate in the activation of innate and adaptive immune cells that orchestrate type 2 airway inflammation. 7, 9, 10, 25 Consistent with its constitutive expression in epithelial cells, 47 Il33 transcripts were readily detected in microdissected airway tissues from naive WT mice and were significantly increased (approximately 14-fold) in Scnn1b-Tg littermates (Fig 4, C) . In contrast, Il25 and Tslp were detected in neither WT nor Scnn1b-Tg airway tissues. In vitro IL-33 induced dose-dependent expression of Il13 in primary airway epithelial cultures from WT and Scnn1b-Tg mice (Fig 4, D, and see Fig E2) . After A fumigatus challenge in vivo, Il33 expression remained increased, and Il25 and Tslp transcripts remained undetectable in airway epithelia from Scnn1b-Tg mice (Fig 4, C) . Il13 transcript levels tended to be increased (approximately 3-fold) in A fumigatus-challenged compared with naive Scnn1b-Tg littermates; however, this difference did not reach statistical significance based on the number of mice included in our studies (Fig 4, C) . Of note, induction of Il13 by IL-33 in airway epithelial cultures in vitro was mediated by ST2/MyD88 signaling and independent of STAT6, whereas allergen-induced airway eosinophilia, increased IL-13 secretion, and GCM in Scnn1b-Tg mice were STAT6 dependent in vivo (Figs 4 and 6) . However, these data do not exclude a role of IL-33 in IL-13 induction in vivo. Recent studies in the intestinal epithelium showed that the in vitro effects of IL-33 were entirely MyD88 dependent and independent of STAT6, whereas the in vivo effects of IL-33 injected in mice were also dependent on STAT6 and IL-13. 52 These results suggest that IL-13 triggered by IL-33 through the ST2/MyD88 signaling pathway might promote autocrine/paracrine activation of IL-13 secretion by the epithelium and other cell types, which in turn depends on STAT6 signaling and is necessary to produce full-blown type 2 inflammation in vivo. 52 Collectively, these results identify the airway epithelium as an important source of IL-13 that might contribute to the orchestration of type 2 inflammation at the mucosal interface. Furthermore, our data suggest that activation of airway epithelial cells by IL-33 released in response to allergens or other danger-associated molecular patterns that accumulate in mucostatic airways might be implicated in triggering this process.
Consistent with an important role of epithelial IL-33 in the pathogenesis of type 2 inflammation triggered by mucociliary dysfunction, we identified T H 2 cells and ILC2s as cellular sources of increased baseline and exaggerated allergen-induced IL-13 production in lungs of Scnn1b-Tg mice (Figs 1 and 4, F) . As expected from previous studies, 16 AMs expressed markers of alternative activation (AAMs) and contributed to IL-13 production in Scnn1b-Tg mice, even in the absence of allergen challenge (Figs 4, F, and 5). In contrast to T H 2 cells and ILC2s, AAMs were not further increased in A fumigatus-challenged Scnn1b-Tg mice (Fig 5) . However, allergen uptake by AMs was reduced in Scnn1b-Tg compared with WT mice. In combination with impaired MCC, this reduced AM-mediated allergen uptake might contribute to impaired clearance and thus overall burden of airborne allergens in the lungs of Scnn1b-Tg mice (Fig 5, E and  F) . Conversely, allergen uptake by cDCs was significantly increased in Scnn1b-Tg compared with WT mice. This enhanced allergen uptake might be due to activation of cDCs in the proinflammatory milieu and/or increased allergen load in mucostatic airways and might contribute to the activation of T H 2 cells observed in the lungs of Scnn1b-Tg mice (Fig 5, G and H) . Taken together, these results demonstrate that mucociliary dysfunction, leading to reduced clearance of inhaled allergens from airway surfaces, triggers activation of innate and adaptive immune cells that contribute to the pathogenesis of type 2 airway inflammation and that the airway epithelium plays an important role in orchestrating this process.
These results also suggest that improvement of slowed mucus clearance might be an effective therapeutic strategy to reduce allergic airway inflammation. To test this hypothesis, we pretreated juvenile Scnn1b-Tg mice and WT littermates with intrapulmonary application of the ENaC blocker amiloride and superimposed challenges with either A fumigatus or HDM on this preventive therapy (Fig 7) . 35 ENaC is limiting for the absorption of Na 1 and fluid from airway surfaces, and airway surface dehydration (mucus hyperconcentration), either because of an imbalance between epithelial Cl 2 secretion and Na 1 absorption or unbalanced mucin secretion, has been identified as a key disease mechanism of mucociliary dysfunction in a spectrum of chronic airway diseases, including asthma. 18, [20] [21] [22] [23] [24] In this context ENaC blockade provides a pharmacologic strategy to improve airway surface hydration and accelerate mucus clearance. 53 Indeed, amiloride and other hydration therapies were shown to improve MCC in patients with CF and other chronic airway diseases [28] [29] [30] ; however, the effects of this intervention on allergen-induced airway inflammation remained unknown.
In a previous study we demonstrated that improving airway surface hydration with preventive amiloride treatment reduced mucus obstruction and spontaneous type 2 inflammation in juvenile Scnn1b-Tg mice to near-normal levels. 35 In the present study we show that continuous amiloride treatment largely prevented exaggerated airway eosinophilia and IL-13 induction in Scnn1b-Tg mice independent of the allergen used (Fig 7, A-H) . In addition, preventive amiloride treatment also protected Scnn1b-Tg mice from allergen-induced AHR (Fig 7, J) . These data provide the first proof of concept that pharmacologic improvement in airway surface hydration and mucus clearance in a susceptible host are an effective therapeutic approach to reduce allergen-induced airway inflammation in patients with chronic airways disease associated with mucociliary dysfunction in vivo.
An interesting finding of our study was the age-dependent susceptibility of mice to develop type 2 airway inflammation in response to allergen challenge in the context of impaired MCC. We show that even short-term exposure to A fumigatus that did not induce airway inflammation in adult mice produced robust type 2 inflammation with airway eosinophilia, increased IL-13 levels, and GCM in juvenile WT mice and that allergen-induced inflammation was exacerbated and associated with AHR in juvenile but not adult Scnn1b-Tg mice (Figs 1 and 2) . We speculate that this enhanced sensitivity originates from a type 22skewed immunity in early life that renders the host susceptible to type 2 inflammation on allergen challenge. 26 This notion is supported by previous studies in WT mice exposed to HDM from the neonatal period showing that allergen-induced airway eosinophilia and type 2 cytokine levels peaked in juvenile mice and waned in adult mice, 27 as well as previous longitudinal studies in naive WT and Scnn1b-Tg mice showing spontaneous increased eosinophil counts, IL-13 levels, and goblet cell counts in juvenile WT mice that were enhanced in Scnn1b-Tg mice and waned in adult mice of both genotypes.
14 In our present study this concept was further corroborated by comprehensive transcripts analyses of a spectrum of type 2 signature genes, including Il13, Muc5ac, Gob5, Arg1, Mmp12, Ym1, Ym2, and Chia. These studies demonstrated that expression levels of Il13, as well as most of the other genes, were increased in lungs from neonatal compared with older WT mice and that this age-dependent type 2 pattern was exacerbated in Scnn1b-Tg mice (Fig 2, D-K) . Interestingly, this pattern included genes exclusively expressed in epithelial cells, such as Muc5ac and Gob5, supporting an important role of the airway epithelium in this age-dependent process. A similar type 2 skewing in early life was reported in human subjects, 54 and this bias persists in many older children and adults with ''T H 2-high'' asthma. 55, 56 Therefore we speculate that our findings in juvenile mice might be applicable to a broader age range in patients with this common asthma endotype. However, future studies will be required to determine the relationship between reduced MCC, allergen-induced airway inflammation, and disease severity in patients with T H 2-high versus T H 2-low asthma. 12, 13, 55, 56 In summary, for the first time, we demonstrate that mucociliary dysfunction causing reduced clearance of inhaled allergens from airway surfaces represents an important risk factor and attractive therapeutic target of allergen-induced type 2 airway inflammation in a susceptible host in vivo. Furthermore, our results support the emerging concept that the airway epithelium is not only an important effector tissue but also an important player in sensing of allergens and transmission of proinflammatory signals to innate and adaptive immune cells that orchestrate the complex in vivo pathogenesis of type 2 inflammation. These results suggest therapeutic improvement of airway mucus clearance as a novel treatment strategy for patients with allergen-induced asthma and potentially other chronic inflammatory airway diseases associated with mucociliary dysfunction.
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Key messages
d Impaired mucus clearance causing reduced clearance of inhaled allergens is an important risk factor for allergen-induced type 2 airway inflammation in juvenile mice.
d The airway epithelium is a key player in sensing of allergens and transmission of signals to innate and adaptive immune cells that orchestrate the complex in vivo pathogenesis of type 2 inflammation.
d Therapeutic improvement of MCC might be a novel treatment strategy for children with allergen-induced asthma.
METHODS Experimental animals
All animal studies were approved by the Regierungspr€ asidium Karlsruhe, Germany (35-9185.81/G-26/14). Scnn1b-Tg mice were studied on a mixed genetic background (C3H/HeN x C57BL/6N) E1,E2 or on the C57BL/6N background. E3 In the colony with mixed genetic background, Scnn1b-Tg mice were bred with C3B6 F1 WT mice (Charles River Laboratories, Sulzfeld, Germany) to prevent a genetic drift, as previously described.
E1,E2 Stat6 2/2 mice E4 obtained on the BALB/c background (Jackson Laboratories, Bar Harbor, Me) were intercrossed with Scnn1b-Tg mice on a mixed (C3H/HeN x C57BL/6N) background to obtain Scnn1b-Tg/Stat6 2/2 , Scnn1b-Tg, Stat6 2/2 , and WT littermates in the F2 generation. Mice were genotyped, as previously described, E1 or as recommended by Jackson Laboratories. Experiments were performed at neonatal (10-day-old), juvenile (2-to 3-week-old), and adult (6-week-old) ages, as indicated in the figure legends, and WT littermates with the respective genetic background served as control animals. All animals were housed in specific pathogen-free animal facilities and had free access to chow and water.
Allergen exposure
Airway allergen exposure was performed with A fumigatus extract (Hollister-Stier Laboratories, Spokane, Wash) or HDM (Dermatophagoides farinae) extract (Greer Laboratories), according to previously established protocols. E5-E9 In brief, mice were anesthetized with 3% isoflurane (Baxter, Deerfield, Ill) in oxygen, and either A fumigatus or HDM dissolved in 0.9% NaCl or 0.9% NaCl alone was administered by means of intratracheal instillation. In the A fumigatus model 20 mL (juvenile mice) or 50 mL (adult mice) of A fumigatus (2 mg/ml) or 0.9% NaCl alone was administered intratracheally every 48 hours a total of 4 times, and end point studies were performed 24 hours after the last allergen exposure. In the HDM model juvenile mice were intratracheally sensitized with 20 mL of HDM (0.5 mg/ mL) or 0.9% NaCl alone on 2 consecutive days, followed by 2 intratracheal challenges with 20 mL of HDM (0.05 mg/mL) or 0.9% NaCl alone on days 11 and 12 after the first HDM exposure, and end point studies were performed 48 hours after the last challenge dose. For HDM exposure during amiloride treatment, neonatal mice were sensitized intranasally with 10 mL of HDM (1 mg/mL) or 0.9% NaCl alone and challenged, as described above.
Amiloride treatment
Amiloride treatment studies were performed, as previously described. E10 In brief, amiloride hydrochloride (Sigma-Aldrich) was dissolved in ddH 2 O, and newborn Scnn1b-Tg mice and WT littermates were anesthetized with isoflurane 3% in oxygen and treated with intranasal instillation of amiloride (10 mmol/L, 1 mL/g body weight, 3 times per day) or equal volumes of vehicle (ddH 2 O) alone for a period of 3 weeks. During treatment, mice were weighed 3 times per day to monitor for loss of body mass because of increased diuresis caused by renal effects of systemically absorbed amiloride, and volume deficits were replaced with subcutaneous injections of isotonic NaCl 0.9%, as previously described. E10 In the third week of treatment, intranasal instillation was replaced by intratracheal instillation, and mice were additionally exposed to A fumigatus or HDM, as described above and shown in Fig 7. End point studies were performed 12 hours after the last amiloride treatment (Fig 7) .
AHR
Mice were anesthetized by means of intraperitoneal injection of 80 mg/kg sodium pentobarbital (Sigma-Aldrich), tracheostomized, and connected to a computer-controlled small animal ventilator (flexiVent; SCIREQ, Montreal, Quebec, Canada) through a 19-gauge intratracheal cannula. After initiating mechanical ventilation, mice were paralyzed by means of intraperitoneal injection of 1.6 mg/kg pancuronium bromide (Sigma-Aldrich). Mice were exposed to PBS aerosol, followed by aerosols containing increasing concentrations of methacholine (range, 0.33-160 mg/mL; Sigma-Aldrich), and respiratory resistance (Rrs) was determined, as previously described. E11,E12 Previous studies demonstrated that absolute Rrs is age and weight dependent in developing mice, and mean values decrease from approximately 4 cmH 2 O.s/mL to approximately 2 cmH 2 O.s/mL (ie, approximately 50%) between 2 and 4 weeks of age. E7 AHR at different methacholine concentrations was determined from the percentage change of Rrs from baseline values to control for this age-and weight-dependent variability. In HDM-induced Scnn1b-Tg mice severe airway obstruction and plugging of cannulae with mucus impeded ventilation, and experiments had to be discontinued at high methacholine concentrations in this experimental group (>32 mg/mL when Scnn1b-Tg mice were challenged with HDM alone [Fig 3] and >80 mg/mL in studies with concurrent instillation of ddH 2 O 3 times per day [Fig 7] ).
BAL cell counts and cytokine measurements
Mice were deeply anesthetized by means of intraperitoneal injection of 120 mg/kg ketamine and 16 mg/kg xylazine (Sigma-Aldrich) and exsanguinated, and the trachea was cannulated. Lungs were lavaged with PBS by using a weight-adjusted volume of 0.035 mL/g body weight. This weightadjusted lavage volume approximates the vital capacity of the developing rodent lung and was used to account for differences in lung size of the age populations of mice included in our study.
E13,E14 BAL was repeated twice, both fractions were pooled and centrifuged at 300g for 5 minutes at 48C, and the cell-free supernatant was collected and stored at 2808C. BAL total and differential cell counts were performed, and cell numbers were determined per milliliter of lavage fluid to improve comparability of results from developing mice with different lung sizes, as previously described.
E2,E10 Concentrations of the type 2 cytokines IL-4, IL-5, and IL-13 were measured in BAL supernatants by using ELISA (R&D Systems) or cytometric bead arrayenhanced sensitivity flex set (BD Biosciences), according to the manufacturer's instructions.
MCC
Mice were anesthetized with intraperitoneal injection of 80 mg/kg sodium pentobarbital (Sigma-Aldrich), the trachea was exposed by means of a median anterior neck incision, and the anterior wall was opened longitudinally to expose the mucosal surface. Yellow-green fluorescent microspheres (Thermo Fisher Scientific) with a diameter of 1.1 mm from a 2% solids solution (approximately 3.6 3 10 10 microspheres/mL) were applied to the mucosal surface of the pars membranacea of the distal trachea. MCC was determined from imaging the elimination of fluorescent beads toward the larynx by using a DFC3000 G camera coupled to a MZ10 F modular stereo microscope and analyzed with Application Suite X software (Leica, Wetzlar, Germany). For quantification of MCC, the decrease in bead-derived fluorescent intensity was measured at the area of bead application, and percentage clearance at t 5 i minutes was calculated as follows: ½12Fluorescence intensity at t 5 i=Fluorescence intensity at t 5 0 3 100:
Allergen clearance
Allergen clearance from the whole lung and the airway lumen was assessed by measuring the elimination of fluorescently labeled A fumigatus extract after intratracheal instillation. A fumigatus extract was fluorescently labeled with Alexa Fluor 647 Microscale Protein Labeling Kit (Life Technologies), according to the manufacturer's instructions. Mice were anesthetized with isoflurane 3% in oxygen, and 2.5 mg of fluorescently labeled A fumigatus extract was administered in a volume of 20 mL dissolved in PBS by means of intratracheal instillation. Mice were killed by means of exsanguination after deep anesthesia through intraperitoneal injection of 120 mg/kg ketamine and 16 mg/ kg xylazine (Sigma-Aldrich) either immediately (t 5 0) or 1 hours after allergen instillation to determine whole-lung allergen clearance. Lungs and tracheas were immediately excised en bloc, placed in PBS with proteinase inhibitor (Roche, Basel, Switzerland), and homogenized, and fluorescence intensity was measured in a plate reader (Perkin Elmer, Waltham, Mass). Baseline (t 5 0) fluorescence intensity (in arbitrary units) did not differ between WT (10,525 6 953, n 5 6) and Scnn1b-Tg mice (10,896 6 877, n 5 5, P 5.78). BAL was performed and fluorescence intensity was measured in BAL fluid supernatants to determine allergen clearance from the airway lumen. Baseline (t 5 0) fluorescence intensity (in arbitrary units) did not differ between WT (17,658 6 1,949, n 5 6) and Scnn1b-Tg (17,492 6 1,677, n 5 7, P 5.87) mice. For quantification of whole lung and airway allergen clearance, the decrease in allergen-derived fluorescent intensity was measured in lung homogenates and BAL supernatants, respectively, and the percentage clearance after 1 hour was calculated as follows:
½12Fluorescence intensity at t51 hour=fluorescence intensity at t 5 0 3 100:
Allergen uptake
Uptake of A fumigatus extract by AMs and cDCs in vivo was determined, as previously described. E15,E16 In brief, mice were anesthetized with isoflurane 3% in oxygen, 2.5 mg of A fumigatus extract labeled with Alexa Fluor 647 was administered in a volume of 20 mL dissolved in PBS by means of intratracheal instillation, and BAL was performed 4 hours after instillation and processed as described below for flow cytometry. Allergen uptake by alveolar macrophages and cDCs was assessed by determining the frequency of A fumigatus-Alexa Fluor 647-positive cells with a BD LSRFortessa cell analyzer and FACSDiva software v8.0.1 (BD Biosciences). For in vitro allergen uptake, BAL was performed, BAL cells were immediately washed with PBS, 50,000 cells were suspended in 100 mL of RPMI-1640 medium (GE Healthcare Life Science, South Logan, Utah), and 1.25 mg of labeled A fumigatus extract was added in a volume of 10 mL of PBS. Cells were incubated for 4 hours, and allergen uptake by AMs and cDCs was assessed, as described for in vivo allergen uptake.
Flow cytometry
Multiparameter flow cytometry was performed with an LSRFortessa flow cytometer (BD Biosciences). For isolation of leukocytes from the lungs, mice were deeply anesthetized through intraperitoneal injection of 120 mg/kg ketamine and 16 mg/kg xylazine and killed by means of exsanguination, and the lungs were perfused with PBS, removed, and placed in RPMI-1640 medium (GE Healthcare Life Science) on ice for immediate processing. Each lung was removed from RPMI-1640 medium, placed into a petri dish, minced with scissors into pieces no larger than 2 to 3 mm, transferred to a 50-mL conical tube with 10 mL of PBS containing 300 U/mL collagenase type II (Worthington Biochemical, Lakewood, NJ) and 0.15 mg/mL DNase I (SigmaAldrich), and incubated on a shaker with an orbital speed of 125 rpm for 30 min at 378C, as previously described.
E17-E19 Digested lung solutions were passed through a 100-mm mesh and subsequently a 40-mm mesh to obtain single-cell suspensions. Red blood cells were lysed with red blood cell lysis buffer (BD Pharm Lyse, BD Biosciences), and single cells were finally resuspended in RPMI-1640 medium. For detection of intracellular IL-13 expression, aliquots of single-cell suspensions containing 1 to 1.5 3 10 6 cells were loaded into 96-well plates and restimulated in vitro with 50 ng/mL phorbol 12-myristse 13-acetate and 1 mg/mL ionomycin (Sigma-Aldrich) in the presence of BD Golgi-Stop (BD Biosciences) for 4 hours, according to the manufacturer's instructions. Next, cells were washed with PBS containing 1% inactivated FBS (Gibco Life Technologies, Darmstadt, Germany) and 0.09% sodium azide (Sigma-Aldrich).
Before surface staining with specific monoclonal fluorochrome-conjugated antibodies or respective isotype control antibodies, cells were incubated with Fc Block (BD Biosciences). For detection of IL-13 
Histology and airway morphology
Lungs were removed through a median sternotomy, fixed in 4% buffered formalin, and embedded in paraffin. To determine goblet cell numbers, left lungs were sectioned transversally at the level of the proximal intrapulmonary main axial airway, and 1.5-mm sections were stained with Alcian blue/ periodic acid-Schiff (Sigma-Aldrich). Goblet cells were identified by the presence of intracellular Alcian blue/periodic acid-Schiff-positive material, and numeric densities were quantified by counting the number of goblet cells per millimeter of basement membrane by using cell F analysis software (Olympus, Hamburg, Germany), as previously described.
E2

Laser microdissection
For laser microdissection, lungs were frozen in liquid nitrogen after inflation with Tissue-Tek O.C.T. compound (Sakura Finetek, Torrance, Calif), and the right superior lobes were sectioned transversally at 10-mm thickness and mounted on MembraneSlides 1.0 PEN (Zeiss, Jena, Germany). Airway epithelium was microdissected and catapulted in an adhesive cap of a microfuge tube (Zeiss) by using the MicroBeam system (PALM Microlaser Technologies, Bernried, Germany), consisting of a 337-nm nitrogen laser integrated into an inverted Axiovert 200 microscope (Zeiss). Microdissected tissue was incubated in lysis buffer, and total RNA was isolated by using the RNeasy Micro Kit (Qiagen), according to the manufacturer's protocol.
Immunohistochemistry
Immunohistochemical staining for IL-13 was performed on formalinfixed, paraffin-embedded lung sections by using a polyclonal goat antimouse IL-13 antibody (R&D Systems) E20 at a dilution of 1:1000. Unstained and hydrated paraffin sections were pretreated for 5 minutes with 3% hydrogen peroxide, followed by antigen retrieval and incubation with a nonspecific protein-blocking solution containing animal serum (Vector Laboratories, Burlingame, Calif), as previously described. E21 Lung sections were incubated overnight at 48C with the primary antibody. A biotinylated rabbit anti-goat IgG was used as a secondary antibody, and immunoreactivity of IL-13 was visualized with Vectastain Elite Kit ABC Reagent, followed by DAB (Vector Laboratories) and hematoxylin (Sigma-Aldrich) counterstaining. As a negative control, each experiment included lung sections stained with secondary antibody only. Numeric densities of IL-13 1 cells within the airway epithelium per millimeter of basement membrane were determined on images taken with an Olympus IX71 microscope interfaced with a DP73 camera using cell F analysis software (Olympus), as previously described. 
